Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second revaccination study of FLU NG versus Fluarix in adults previously enrolled in study 111737
NL-OMON33157Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, single-blind trial of GSK2186877A and Fluarix in influenza (3 arms), sponsored by GSK. Primary endpoints: Solicited local adverse events, Solicited general adverse events and 4 more. Started Oct 2009; status: active, not recruiting.
02
Drugs
GSK2186877AFluarix
03
Conditions
influenza
Beyond the preview
Go deeper on NL-OMON33157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33157.